| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 2269.9 | 2751.8 | 1933.7 |
| Other income | 89.4 | 46.1 | 58.4 |
| Total income | 2359.3 | 2797.8 | 1992.1 |
| Profit before exceptional items & tax | -7.5 | 218.8 | -99.8 |
| Exceptional items | 0.0 | -175.8 | 20.7 |
| Profit before tax | -7.5 | 43.0 | -79.0 |
| Net profit | -69.4 | -8.8 | -81.7 |
| Operating margin | -0.3% | 1.5% | -4.0% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Revenue, year on year | +17.40% |
|---|---|
| Operating profit, year on year | -13.30% |
| Operating profit, quarter on quarter | -189.30% |
NSE results filing, NSE: PPLPHARMA. Figures extracted from the filing.
Piramal Pharma Ltd: key numbers
- Share price
- ₹210.31
- Market cap
- ₹28,000 Cr
- Revenue (annual)
- ₹8,869 Cr
- Net profit (annual)
- ₹-325.9 Cr
- P/E (TTM)
- -89.3×Sector 50.4×
- Promoter holding
- 34.80%-0.06% QoQ
- FII holding
- 12.51%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Piramal Pharma Ltd
All →Piramal Pharma Other Announcement
Piramal Pharma Limited informed exchanges that Niche99 has independently assigned it an ESG rating of 67.1 (ESG Band: Leader), without any company engagement.
Piramal Pharma Business Update
Piramal Pharma reported that the US FDA issued a Form-483 with 7 observations following a GMP inspection of its Morpeth, UK facility.
Piramal Pharma Other Announcement
Piramal Pharma Limited received an improved ESG rating of 65 from NSE Sustainability Ratings and Analytics. The rating was assigned voluntarily based on public disclosures.
Piramal Pharma Investor Presentation: Key Takeaways
Piramal Pharma started FY27 with 17% revenue growth and 72% EBITDA expansion. Momentum was driven by CDMO recovery and power brands.
Piramal Pharma Q4 FY26 Results: Net Loss of ₹8.8 Cr
Piramal Pharma Ltd reported revenue from operations of ₹2,752 Cr (-0.1% YoY) and a net loss of ₹8.8 Cr for Q4 FY26.
- Key figure
- Net loss ₹8.8 Cr